← All trials
NCT05587205
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2022
- Primary completion
- Nov 30, 2023
- Completion date
- Jun 1, 2024
- First posted
- Oct 19, 2022
- Last posted
- Dec 2, 2022
- Enrollment
- 32
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Asociación para Evitar la Ceguera en MéxicoLead sponsor
- Asociación para Evitar la Ceguera en MéxicoOverall official - principal investigator
- EmmecellCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.